<p><h1>Nicotinamide Phosphoribosyltransferase Market Size Growing and Forecasted for period from 2024 - 2031 and provides complete market analysis of this market</h1></p><p><strong>Nicotinamide Phosphoribosyltransferase Market Analysis and Latest Trends</strong></p>
<p><p>Nicotinamide phosphoribosyltransferase (NAMPT) is an enzyme that plays a critical role in the biosynthesis of nicotinamide adenine dinucleotide (NAD+), an essential coenzyme involved in various cellular processes such as energy metabolism, DNA repair, and regulation of gene expression. NAMPT catalyzes the conversion of nicotinamide to nicotinamide mononucleotide (NMN), which is then further converted to NAD+.</p><p>The Nicotinamide Phosphoribosyltransferase Market is expected to witness significant growth during the forecast period. The increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases has led to an increased demand for NAMPT inhibitors, which has significantly contributed to the market growth. NAMPT inhibitors are being investigated as potential therapeutic agents for the treatment of various diseases, including cancer, due to their ability to inhibit tumor growth and enhance the effectiveness of chemotherapy.</p><p>Moreover, the growing focus on personalized medicine and targeted therapies has further fueled the demand for NAMPT inhibitors. The development of novel NAMPT inhibitors with improved efficacy and safety profiles has also positively impacted the market growth.</p><p>In addition, the rising investments in research and development activities in the field of NAMPT inhibitors by pharmaceutical companies and academic institutions are expected to drive market growth. Furthermore, the increasing adoption of NAMPT inhibitors in preclinical and clinical trials for the treatment of various diseases is anticipated to boost market growth in the coming years.</p><p>Overall, the Nicotinamide Phosphoribosyltransferase Market is projected to grow at a CAGR of 7.8% during the forecast period, driven by the increasing demand for NAMPT inhibitors in the treatment of various diseases and ongoing research and development activities in this field.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1564136">https://www.reliableresearchreports.com/enquiry/request-sample/1564136</a></p>
<p>&nbsp;</p>
<p><strong>Nicotinamide Phosphoribosyltransferase Major Market Players</strong></p>
<p><p>The nicotinamide phosphoribosyltransferase (NAMPT) market is highly competitive, with several key players operating in the field. Some of the prominent market players include Genentech, Inc., Angelini Group, Calico LLC, FORMA Therapeutics, Inc., OncoTartis, Inc., Karyopharm Therapeutics, Inc., and Aurigene Discovery Technologies Limited.</p><p>Genentech, Inc., a subsidiary of Roche Holding AG, is a leading player in the NAMPT market. The company focuses on developing innovative therapies for various diseases, including cancer. Genentech's drug candidate, GDC-0077, is a potential NAMPT inhibitor currently in clinical trials. The company has shown significant market growth in recent years, aided by its strong pipeline and robust research capabilities.</p><p>Angelini Group is an Italian pharmaceutical company with a strong presence in the NAMPT market. The company has developed a novel NAMPT inhibitor called CG-200745, which has shown promising results in preclinical studies for the treatment of tumors. Angelini Group is actively expanding its market reach through strategic collaborations and partnerships worldwide.</p><p>Calico LLC, a subsidiary of Alphabet Inc., is a major player in the NAMPT market. The company focuses on developing therapeutics for age-related diseases, including cancer. Calico is involved in several research projects aiming to identify NAMPT modulators and their potential in treating various diseases associated with aging. The company's strong financial backing and access to cutting-edge technologies have positioned it for future growth in the market.</p><p>FORMA Therapeutics, Inc. is a biopharmaceutical company renowned for its expertise in drug discovery and development. The company has a robust NAMPT program, with multiple small molecule inhibitors in its pipeline. FORMA Therapeutics' lead candidate, FT-857, has shown promising results in preclinical models of cancer. The company's strategic collaborations, including a partnership with Genentech, further support its market growth potential.</p><p>While specific sales revenue figures were not available, it is important to note that the global NAMPT market is projected to witness substantial growth in the coming years. Factors such as the increasing prevalence of cancer and other age-related diseases, along with advancements in drug discovery technologies, are driving market expansion. Additionally, the demand for innovative therapies targeting NAMPT remains high, presenting significant opportunities for market players to capitalize on.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Nicotinamide Phosphoribosyltransferase Manufacturers?</strong></p>
<p><p>Nicotinamide Phosphoribosyltransferase (NAMPT) is an enzyme involved in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). The market for NAMPT is witnessing significant growth due to its potential applications in various therapeutic areas, including oncology, neurology, and metabolic disorders. Extensive research is being conducted to understand the role of NAMPT in diseases and develop targeted therapeutics. The market is expected to witness a steady growth rate over the coming years, driven by the rising prevalence of chronic diseases and increasing demand for personalized medicine. However, challenges related to the high cost of NAMPT inhibitors and complex regulatory pathways need to be overcome for market success.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1564136">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1564136</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Nicotinamide Phosphoribosyltransferase Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Hormone</li><li>Lipids</li><li>Small Molecule Compounds</li><li>Others</li></ul></p>
<p><p>Nicotinamide Phosphoribosyltransferase (NAMPT) market types can be categorized into four groups: hormone, lipids, small molecule compounds, and others. The hormone market refers to the use of NAMPT in regulating the production or activity of certain hormones within the body. The lipids market involves the utilization of NAMPT in lipid metabolism and regulation. The small molecule compounds market focuses on the utilization of NAMPT inhibitors or activators in drug development. Lastly, the others market includes other applications of NAMPT that do not fall under the previous categories.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/1564136">https://www.reliableresearchreports.com/purchase/1564136</a></p>
<p>&nbsp;</p>
<p><strong>The Nicotinamide Phosphoribosyltransferase Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Parkinson's Disease</li><li>Acute Lung Injury</li><li>Breast Cancer</li><li>Others</li></ul></p>
<p><p>Nicotinamide Phosphoribosyltransferase (NAMPT) is a key enzyme involved in cellular energy metabolism. In the context of Parkinson's Disease, NAMPT inhibitors are being investigated as potential therapeutics to modulate neuroinflammation and improve neuronal function. In Acute Lung Injury, NAMPT inhibitors may help reduce lung inflammation and tissue damage. In Breast Cancer, NAMPT is overexpressed in tumor cells and targeting it could inhibit cancer cell growth. NAMPT inhibitors also show potential in other diseases where inflammation or abnormal cell growth play a role.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Nicotinamide Phosphoribosyltransferase Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The Nicotinamide Phosphoribosyltransferase (NAMPT) market is anticipated to witness substantial growth across various regions, including North America (NA), Asia-Pacific (APAC), Europe, the USA, and China. In terms of market dominance, North America is expected to lead the way with an estimated market share of around 35%. This can be attributed to the rising prevalence of chronic diseases and the increasing adoption of personalized medicine in the region. Asia-Pacific is projected to witness significant growth as well, capturing a market share of approximately 30%, driven by advancements in healthcare infrastructure and increasing healthcare expenditure. Europe is anticipated to hold a market share of around 25%, mainly due to the rising geriatric population and growing awareness regarding NAMPT-based therapeutics. The USA and China are predicted to hold market shares of approximately 5% and 3%, respectively, owing to factors like increasing research activities and the presence of key market players in these regions.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/1564136">https://www.reliableresearchreports.com/purchase/1564136</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/1564136">https://www.reliableresearchreports.com/enquiry/request-sample/1564136</a></p>
<p><strong></strong></p>
<p>Check more reports on https://www.reliableresearchreports.com/</p>